Vedolizumab and ustekinumab can both be considered for treatment in CD when conventional and anti-TNF medication fail.
As head-to-head trials are not available and methodological issues limit an indirect comparison based on the registration studies, Biemans et al. compared vedolizumab- and ustekinumab-treated CD patients in a real-life systematic observational cohort (Initiative on Crohn and Colitis case series) . They reported that clinical remission and AEs were comparable between treatments after 24 weeks.
CD patients receiving either vedolizumab or ustekinumab in standard care were followed using predefined follow-up visits (at 0, 12, 24, 52, and 104 weeks). CD characteristics documented included clinical disease activity (HBI), inflammatory markers (CRP, FCP), hospital admissions, CD-related surgery and AEs. Clinical remission was defined as HBI <5. As the aim was to compare treatments, patients with a history of both studied treatment...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Diagnostic techniques for IBD: the ECCO-ESGAR Guidelines Next Article
Higher rates of remission and healing with vedolizumab vs. TNF antagonist »